Copley Acquisition Corp is set to merge with Ignite Proteomics in a deal valued at $150 million. The merger aims to create a new public holding company where both entities will operate as units. Ignite will separate from Aditxt but continue to focus on its cancer-testing technology.
Company Information
Company
Copley Acquisition
Location
Boston, Massachusetts, United States
About
Copley Acquisition Corp. is a special purpose acquisition company (SPAC) that aims to merge with or acquire another business. SPACs are shell companies created to raise capital through an initial public offering (IPO) for the purpose of acquiring an existing company. The goal is to take the acquired company public without going through the traditional IPO process. Copley focuses on identifying promising companies in need of capital and support for rapid growth.
Don't miss Copley Acquisition's next move
Get an email the moment Copley Acquisition makes an acquisition, hires an exec, or expands, usually minutes after it happens.
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed
Frequently asked
Who acquired Ignite Proteomics?
Ignite Proteomics was acquired by Copley Acquisition, based in Boston. The deal was reported on June 11, 2026. Copley Acquisition Corp. is a special purpose acquisition company (SPAC) that aims to merge with or acquire another business. Copley Acquisition is publicly traded (COPL) and operates in Software.
When did Copley Acquisition acquire Ignite Proteomics?
Copley Acquisition's acquisition of Ignite Proteomics was reported on June 11, 2026. Copley Acquisition Corp is set to merge with Ignite Proteomics in a deal valued at $150 million. The merger aims to create a new public holding company where both entities will operate as units. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Ignite Proteomics do?
Ignite Proteomics is a commercial-stage precision oncology company that addresses challenges in cancer care through optimizing therapy selection. It is privately held, operating in Biotechnology, and is based in United States.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.